Humana Stock Earnings Reports

Humana reported a first quarter in line with expectations and reiterated its Investor Day commitments to return to a sustainable Medicare Advantage (MA) margin of at least 3% by 2028 with progress in 2027. Management is focused on four drivers: product & experience (member growth and retention), clinical excellence (Stars improvement), operational efficiency (centralization, outsourcing, automation) and disciplined capital allocation (CenterWell expansion and balance-sheet optimization). Early indicators (risk scores, admits, pharmacy, initial medical claims) for new and existing MA members are tracking in line to better than guidance through April. The company will approach 2027 MA bids with pricing and benefit adjustments as necessary to bridge the gap between program funding and medical cost trend while prioritizing retention and market-level actions. Humana continues to invest in Stars improvement (targeting top-quartile BY '28), and CenterWell saw strong patient and patient-source growth (including the Max Health acquisition), though CenterWell experienced some one-time and timing-related costs in Q1. On capital, Humana completed $1B of junior subordinated notes, mitigated over $3B of 2026 capital contribution requirements via reinsurance/legal-entity actions, is limiting buybacks to offset dilution (maintaining dividends), and is pursuing non-core divestitures and disciplined M&A funding plans (including contingency for possible Welsh Carson put exercises). Management emphasized enhanced claims monitoring, anomaly detection, and a transformation office driving execution across initiatives.